Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER-2 Positive Metastatic Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00331552
What this trial is testing

Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer

Who this might be right for
HER2-positive Breast CancerMale Breast CancerRecurrent Breast Cancer+1 more
University of Washington 30
Large-scale testing (Phase 3)Active Not RecruitingNCT04711252
What this trial is testing

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

Who this might be right for
ER-Positive HER2-Negative Breast Cancer
AstraZeneca 1,370
Testing effectiveness (Phase 2)Study completedNCT03007992
What this trial is testing

Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Johannes Gutenberg University Mainz 9
Large-scale testing (Phase 3)Study completedNCT01764022
What this trial is testing

A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients

Who this might be right for
Human Epithelial Receptor (HER)-2 Positive Breast Cancer
Biocad 225
Testing effectiveness (Phase 2)Study completedNCT01835236
What this trial is testing

Trastuzumab & Pertuzumab Followed by T-DM1 in MBC

Who this might be right for
Metastatic Breast Cancer
Swiss Cancer Institute 208
Not applicableUnknownNCT06015100
What this trial is testing

Efficacy and Safety of Inetetamab Plus Pyrotiniband and Capecitabine in HER2-positive Metastatic Breast Cancer Patients With or Without Brain Metastasis

Who this might be right for
Breast Cancer
Yan Xue 40
Testing effectiveness (Phase 2)Study completedNCT01783444
What this trial is testing

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 309
Testing effectiveness (Phase 2)Active Not RecruitingNCT04829604
What this trial is testing

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

Who this might be right for
HER2 Positive Metastatic Breast Cancer
Ambrx, Inc. 72
Testing effectiveness (Phase 2)Study completedNCT05963984
What this trial is testing

Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast CancerBreast Cancer
Carrick Therapeutics Limited 60
Not applicableStudy completedNCT01081600
What this trial is testing

89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition

Who this might be right for
Breast Cancer
University Medical Center Groningen 7
Testing effectiveness (Phase 2)Ended earlyNCT05932667
What this trial is testing

Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer

Who this might be right for
Advanced or Metastatic Breast Cancer
Institut Curie 1
Not applicableStudy completedNCT01615068
What this trial is testing

An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)

Who this might be right for
Breast Cancer
Genentech, Inc. 1,007
Testing effectiveness (Phase 2)Ended earlyNCT04298918
What this trial is testing

A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 1
Early research (Phase 1)UnknownNCT01304797
What this trial is testing

Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer

Who this might be right for
Breast Cancer
Merrimack Pharmaceuticals 75
Testing effectiveness (Phase 2)Study completedNCT00741260
What this trial is testing

Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer

Who this might be right for
Breast Cancer
Puma Biotechnology, Inc. 105
Not applicableStudy completedNCT06705504
What this trial is testing

A Real-world Study of Effectiveness and Safety in HR+/HER2- Breast Cancer Patients Treated With Ribociclib or Alpelisib

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast Cancer
Novartis 435
Testing effectiveness (Phase 2)Study completedNCT00670982
What this trial is testing

Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Harold J. Burstein, MD, PhD 29
Testing effectiveness (Phase 2)Looking for participantsNCT05150691
What this trial is testing

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

Who this might be right for
HER2-positive Advanced Solid Tumor
DualityBio Inc. 796
Testing effectiveness (Phase 2)Study completedNCT02035813
What this trial is testing

DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).

Who this might be right for
HER2-negative and Hormone-receptor Positive Metastatic Breast CancerHER2-negative Circulating Tumor CellsPostmenopausal Female Patients
Prof. Wolfgang Janni 116
Testing effectiveness (Phase 2)Ended earlyNCT04142060
What this trial is testing

Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 34
Next Page